Predilife: 2025 Review and Advances in Predictive Medicine

In 2025, Predilife, a company specializing in artificial intelligence for disease prediction, made history with the clinical validation of early cancer screening. The American Wisdom study, launched in 2016 with 28,000 women, demonstrated that 37% of advanced cancers were detected at an early stage. The MammoRisk model, comparable to Wisdom, benefits from this major breakthrough.

In the United States, Predilife has submitted an application for FDA approval for its Denseerisk device, which combines image analysis and risk assessment. This device represents a major advancement compared to already approved solutions.

Despite a projected increase in revenue to €836,000 in 2025, the company posted a net loss of €3.9 million. Cash reserves allow it to plan for the future until the end of 2026, with the court-approved restructuring plan providing a reprieve for restructuring and leveraging its assets.